Polyrizon Completes All Five Clinical Sites for NASARIX™ Trial, Moves Toward 120-Patient Enrollment
PLRZ has more than doubled off its 52-week low of $2.88.
Summary
Polyrizon completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker trial and disclosed full study design, advancing toward enrollment of 120 patients timed to allergy seasons.
Key Events · Product Development and Regulatory · PLRZ
-
All Five Clinical Sites Contracted
Polyrizon completed agreements with the fourth and fifth U.S. clinical sites, finalizing the full network for the NASARIX™ Allergy Blocker study.
-
Trial Design Disclosed
The first-in-human study is a prospective, multicenter, randomized, single-blind, two-arm trial enrolling up to 120 patients in a 1:1 ratio to NASARIX™ or isotonic saline control.
-
Primary Endpoint Set
Efficacy will be measured by mean daily reflective Total Nasal Symptom Score (rTNSS) over the first 14 treatment days, with safety assessed via adverse events and tolerability.
-
Enrollment Timing Tied to Allergy Seasons
Patient pre-screening and enrollment will coincide with seasonal allergen exposure, with local pollen counts and weather monitored to support recruitment timing.
Analysis · PLRZ · Industrial Applications And Services
Polyrizon has now contracted all five U.S. clinical sites for its NASARIX™ Allergy Blocker first-in-human study, a key operational milestone that shifts the program from preparation to execution. The filing details the trial design: 120 patients randomized 1:1 to NASARIX™ or saline control, with a primary endpoint of rTNSS over 14 days. Enrollment is timed to allergy seasons, meaning patient recruitment will ramp as pollen counts rise. This is a meaningful step for a development-stage biotech with a $22.8M market cap, as it de-risks the clinical timeline and brings the company closer to generating efficacy data that could support U.S. market entry.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLRZ was trading at $10.96 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22.8M. The 52-week trading range was $2.88 to $18.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.